-
Temozolomide Workflows for Glioma DNA-Damage Studies
2026-08-14
Temozolomide (SKU B1399) provides a practical way to model alkylation-driven DNA damage, growth inhibition, and treatment response in glioma and other cancer systems. This guide connects reliable DMSO handling with ATRX-aware combination experiments, dose-response design, and troubleshooting for more interpretable results.
-
Protease Inhibitor Cocktail EDTA-Free: K1007 Guide
2026-08-14
The Protease Inhibitor Cocktail EDTA-Free is a 100X DMSO concentrate for reducing proteolytic degradation during protein extraction and cell-lysate preparation. Its EDTA-free design supports workflows in which added chelators could interfere with divalent-cation-sensitive enzymes, including phosphorylation analysis and kinase assays.
-
SU5416 (Semaxanib): Reliable Assay Workflows
2026-08-13
Learn how SU5416 (Semaxanib), SKU A3847, can improve the interpretation and reproducibility of endothelial proliferation, viability, and angiogenesis experiments. This scenario-driven guide covers mechanism, solvent handling, concentration selection, model limitations, and evidence-based product evaluation.
-
AEBSF.HCl in Necroptosis and Protease Assays
2026-08-13
AEBSF.HCl provides irreversible serine protease control for cell lysis, protease assays, amyloid pathway experiments, and mechanistic necroptosis studies. Its greatest value is as an orthogonal reagent that separates serine-protease background from the cathepsin-driven events identified in lysosomal membrane permeabilization.
-
KDM3A–METTL16–PDK1 Axis in TKI Resistance
2026-08-12
This study identifies a linked epigenetic and mRNA-modification mechanism that elevates PDK1 and promotes EGFR-TKI resistance and tumor development. Its findings connect KDM3A-driven chromatin remodeling with METTL16–IGF2BP1 regulation of PDK1 mRNA, providing a mechanistic framework for biomarker development and combination therapy studies.
-
IPI7–IPA1 Ubiquitination in Rice Immunity
2026-08-12
The reference study identifies the RING-finger E3 ligase IPI7 as a co-activator that enables phosphorylated IPA1 to activate WRKY45 during Magnaporthe oryzae infection. Its central innovation is showing that K29-linked polyubiquitination can regulate transcription-factor activity without destabilizing the substrate, thereby separating immune activation from IPA1-dependent yield traits.
-
Chlorpromazine: A Perturbation Tool for Nanomedicine
2026-08-11
Chlorpromazine hydrochloride offers a pharmacological lens for interpreting heterogeneous hepatic nanoparticle uptake. This article connects dopamine receptor signaling with the size- and PEG-dependent findings of a 2026 ACS Nano study while defining practical assay controls and cross-domain limitations.
-
CLK2, BRCA1, and Platinum Resistance in Ovarian Cancer
2026-08-11
The reference study identifies Cdc2-like kinase 2 (CLK2) as a determinant of platinum resistance in ovarian cancer and defines a CLK2–BRCA1 phosphorylation axis that enhances DNA damage repair. Its combination of tissue profiling, cell-based platinum-response assays, mechanistic analysis, and xenograft validation provides a framework for evaluating CLK2 as a resistance-associated therapeutic target.
-
DiscoveryProbe Natural Product Library Plus: Assay Logic
2026-08-10
DiscoveryProbe Natural Product Library Plus supports a decision-driven strategy for natural product screening, combining chemical diversity with automation-ready assay design. This article shows how metabolic target evidence from Cryptosporidium research can guide biochemical, phenotypic, and high-content follow-up without overstating validation.
-
Ruxolitinib Phosphate: From JAK to Mitochondria
2026-08-09
Ruxolitinib phosphate (INCB018424) is more than a conventional JAK1/JAK2 research tool. Recent evidence in anaplastic thyroid carcinoma connects JAK/STAT signaling pathway modulation to DRP1-dependent mitochondrial dynamics, apoptosis, and GSDME-mediated pyroptosis. This thought-leadership guide translates those findings into practical strategies for disease modeling, assay design, compound positioning, and translational decision-making.
-
ST3GAL1 Sialylation Drives F. nucleatum Adhesion
2026-08-08
The reference study identifies ST3GAL1-dependent sialylation as a host-cell determinant of Fusobacterium nucleatum adhesion to colorectal cancer cells. Its findings connect altered surface glycans with sustained bacterial colonization and an H3K27ac/ANGPTL4 cancer-promoting axis, providing a mechanistic framework for studying intratumoral microbial persistence.
-
CUX2 Neuron Loss and DNA Damage in Neuroinflammation
2026-08-07
The reference study identifies accumulated DNA damage and insufficient repair as a major contributor to the selective loss of CUX2-positive layer 2/3 excitatory neurons during multiple sclerosis-associated neuroinflammation. By integrating human MS tissue, inflammatory mouse models, neuronal perturbation experiments, and interferon-γ exposure, it connects inflammatory oxidative stress with cell-type-specific neuronal vulnerability.
-
TP53-Dependent DHODH Inhibition in NPC: Mechanisms and Impli
2026-08-07
Dong et al. provide the first comprehensive evidence that targeting dihydroorotate dehydrogenase (DHODH) in nasopharyngeal carcinoma (NPC) yields potent antitumor effects primarily through a TP53-dependent mechanism. This work establishes nucleic acid metabolism as a crucial driver of NPC progression and highlights the therapeutic promise of DHODH inhibition in tumors with functional TP53.
-
Eliminating Chemotherapy-Induced Senescent Cells in TP53 Wil
2026-08-06
This study demonstrates that BH3 mimetics can selectively eliminate chemotherapy-induced senescent cells in TP53 wild-type breast cancer, a setting where standard therapies often fail to induce tumor cell death. By targeting antiapoptotic BCL-2 family proteins, the research provides a mechanistic foundation for combining senolytic agents with chemotherapy to improve outcomes in poor-prognosis breast cancers.
-
MDL 28170: Calpain Inhibition for Translational Neuroprotect
2026-08-06
Discover how MDL 28170, a selective calpain inhibitor, advances neuroprotection and experimental design in translational neuroscience. This article explores mechanistic depth, protocol nuances, and cross-domain implications beyond standard assay workflows.